Vacinação Anti‐amarílica Em Pacientes Com Doenças Reumáticas Imunomediadas: Análise Retrospectiva

Lira, Kamila; Balarini, L.; Lima, Sheyla Maria Lemos; Azevedo, Alba Cristina Cardoso de; Carvalho, Andréa Teixeira; Paschoal, V.P.M.; Myiamoto, S.T.; Souza, Adrielle Lopes; Rocha, Priscila Costa Martins; Zanon, Thiarla Xavier Dal-Cin; Serrano, Érica Vieira; Duque, Ruben Horst; Gavi, M.B.R.O.; Dinis, Vitor; Caser, Larissa Carvalho; Salume, F.L.C.; Dalmaso, Ana Sílvia Whitaker; Burian, Aleš; Pinto, Luciane; Brandão,; Polito, Elizandra; Clemente, T.B.; Magalhães, E.S.; Rodrigues, Lívia Carla de Melo; Morello, Flavia; Oliveira, K.G. De; Thebit, M.M.; Bissoli, M.F.; Gouvêa, Sônia Alves; Assis, Ohana Almeida de Sousa; Moura, L.D.M. De; Valim, Valéria

doi:10.1016/j.rbr.2017.06.119

Cited by 1 publication

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The participants were subjects who had received the YFV despite a diagnosis of CIMID and no SAE was reported. There was no difference in AEFV occurrence between patients and healthy individuals [35,[41][42][43][44][45][46][47][48].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…All included studies had methodological limitations regarding the design or development and did not describe adequate statistical analysis data to evaluate the magnitude of effect. In addition, we only had access to the partial results of three included studies at the time of our review, as they were conference abstracts from ongoing studies [43,46,47]. For this reason, we could not estimate the effect or quality of evidence.…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

See 1 more Smart Citation

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

et al. 2019

View full text Add to dashboard Cite

Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the (Continued on next page)

show abstract